Sponsor Check › Person
Related person on Form D filings · address states as listed: NJ, CA, CO, MA, FL · listed May 17, 2010 → Jan 13, 2021
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:58 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this person.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 50 offerings report sales commissions totalling $4,825,998; 1 reports finder's fees totalling $500,000; 1 reports proceeds to related persons totalling $2,000,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Oct 27, 2023 D File 021-495843 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 23, 2022 D File 021-446531 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 3, 2022 D File 021-435814 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2021 D File 021-421863 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 25, 2021 D/A File 021-400773 | $0 | $500,000 (est.) | $0 | JMP SECURITIES LLC BrokerCheck CRD 22208 ↗ |
| EDGAR ↗ | Jan 13, 2021 D File 021-386220 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 13, 2021 D File 021-386222 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 3, 2020 D/A File 021-346766 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 22, 2020 D File 021-367556 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 24, 2019 D File 021-342556 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 16, 2019 D File 021-337466 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 21, 2018 D File 021-326396 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 15, 2017 D File 021-294795 | $2,825,998 | $0 | $0 | Piper Jaffray & Co. BrokerCheck CRD 665 ↗ |
| EDGAR ↗ | Jun 29, 2017 D/A File 021-275764 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 25, 2017 D File 021-285438 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 16, 2016 D File 021-276496 | $2,000,000 | $0 | $0 | PIPER JAFFRAY & CO. BrokerCheck CRD 665 ↗ |
| EDGAR ↗ | Dec 7, 2016 D/A File 021-230865 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 2, 2016 D/A File 021-274603 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 22, 2016 D File 021-275027 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 15, 2016 D File 021-265133 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 14, 2015 D File 021-249344 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 15, 2015 D File 021-241781 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 2, 2015 D File 021-237156 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 19, 2015 D File 021-234341 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Dec 22, 2014 D/A File 021-227129 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 29, 2014 D File 021-221960 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 10, 2014 D File 021-218873 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 4, 2014 D/A File 021-211134 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 27, 2013 D File 021-207178 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 25, 2013 D File 021-203489 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 9, 2013 D File 021-199252 | $0 | $0 | $0 (est.) Proceeds will be used for general corporate purposes including, but not limited to, executive salaries | None listed on this filing |
| EDGAR ↗ | Dec 28, 2012 D/A File 021-168548 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 24, 2012 D File 021-188915 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 1, 2012 D File 021-182089 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 14, 2012 D File 021-179780 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 25, 2012 D File 021-178807 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2012 D File 021-177399 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 30, 2011 D File 021-165134 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 13, 2011 D File 021-159761 | $0 | $0 | $2,000,000 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 9, 2011 D File 021-156454 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 2, 2011 D File 021-156098 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 1, 2010 D File 021-149853 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 16, 2010 D File 021-147844 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 14, 2010 D File 021-144943 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 17, 2010 D File 021-142154 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 21, 2009 D File 021-96789 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 15, 2009 D/A File 021-94611 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 27, 2009 D/A File 021-109432 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 18, 2009 D File 021-132078 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 10, 2009 D File 021-131856 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | Oct 27, 2023 | D | $24,000,000 similar: $1,694,259–$16,000,000 | $11,054,030 | 35 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | InflammX Therapeutics, Inc. | Director | May 23, 2022 | D | Indefinite similar: $2,000,000–$19,999,994 | $0 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ChromaCode, Inc. | Director | Mar 3, 2022 | D | $50,685,025 similar: $2,000,000–$19,999,994 | $27,967,512 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | InflammX Therapeutics, Inc. | Director | Nov 19, 2021 | D | $8,355,060 similar: $2,000,000–$19,999,994 | $8,355,060 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | Oct 25, 2021 | D/A | $37,806,866 similar: $1,694,259–$16,000,000 | $27,352,547 | 38 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | May 26, 2021 | D | $20,000,000 similar: $1,694,259–$16,000,000 | $4,765,696 | 30 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | InflammX Therapeutics, Inc. | Director | Jan 13, 2021 | D | $7,029,425 similar: $2,000,000–$19,999,994 | $7,029,425 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | Jan 13, 2021 | D | $9,125,807 similar: $2,000,000–$19,999,994 | $9,125,807 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ChromaCode, Inc. | Director | Dec 3, 2020 | D/A | $41,248,842 similar: $2,000,000–$19,999,994 | $38,643,880 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | May 22, 2020 | D | $8,000,000 similar: $1,694,259–$16,000,000 | $7,825,000 | 21 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ChromaCode, Inc. | Director | Aug 16, 2019 | D | $37,792,492 similar: $2,000,000–$19,999,994 | $26,093,882 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | Jun 24, 2019 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $5,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ChromaCode, Inc. | Director | Apr 16, 2019 | D | $3,500,000 similar: $2,000,000–$19,999,994 | $1,750,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | Nov 21, 2018 | D | $28,000,000 similar: $1,694,259–$16,000,000 | $20,026,439 | 36 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | aTYR PHARMA INC | Director | Sep 15, 2017 | D | $45,849,982 similar: $2,000,000–$19,999,994 | $45,849,982 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | Jun 29, 2017 | D/A | $19,150,000 similar: $2,000,000–$19,999,994 | $19,150,000 | 16 similar: 2–16 | $150,000 similar: $10,000–$50,000 |
| EDGAR ↗ | ChromaCode, Inc. | Director | Apr 25, 2017 | D | $12,136,023 similar: $829,831–$9,999,998 | $12,024,997 | 9 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Dec 16, 2016 | D | $43,032,359 similar: $500,000–$7,000,000 | $43,032,359 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Domain Partners IX, L.P. group: Domain | Executive Officer | Dec 7, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $163,636,363 | 6 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | AXIAL THERAPEUTICS, INC. | Director | Dec 7, 2016 | D | $19,150,000 similar: $2,000,000–$19,999,994 | $9,575,000 | 16 similar: 2–16 | $150,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Dec 2, 2016 | D/A | Indefinite similar: $500,000–$7,000,000 | $3,000,300 | 17 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Gene Sciences, Inc. | Executive Officer, Director | Nov 22, 2016 | D | $12,000,000 similar: $829,831–$9,999,998 | $8,000,045 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Nov 16, 2016 | D | Indefinite similar: $500,000–$7,000,000 | $2,000,200 | 13 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | Jun 15, 2016 | D | $2,500,000 similar: $2,000,000–$19,999,994 | $753,986 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Domain Partners IX, L.P. group: Domain | Executive Officer | Dec 3, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $163,636,363 | 6 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Oct 14, 2015 | D | $28,000,000 similar: $500,000–$7,000,000 | $19,999,999 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | Jun 15, 2015 | D | $3,431,328 similar: $2,000,000–$19,999,994 | $1,206,379 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | aTYR PHARMA INC | Director Non-Management Director | Apr 2, 2015 | D | $76,278,755 similar: $2,000,000–$19,999,994 | $76,278,755 | 42 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | Feb 19, 2015 | D | $3,240,200 similar: $2,000,000–$19,999,994 | $1,002,656 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Domain Partners IX, L.P. group: Domain | Executive Officer | Dec 24, 2014 | D | Indefinite similar: $155,000–$5,250,000 | $163,636,363 | 6 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Wireless Diagnostic Systems, Inc. | Director | Dec 22, 2014 | D/A | $1,207,500 similar: $1,100,015–$10,001,163 | $1,207,500 | 3 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Wireless Diagnostic Systems, Inc. | Director | Oct 27, 2014 | D | $1,007,500 similar: $1,100,015–$10,001,163 | $503,750 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Jul 29, 2014 | D | $20,099,393 similar: $500,000–$7,000,000 | $20,091,278 | 35 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | Jun 10, 2014 | D | $5,838,420 similar: $2,000,000–$19,999,994 | $2,510,890 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Mar 4, 2014 | D/A | Indefinite similar: $500,000–$7,000,000 | $4,984,083 | 31 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Jan 31, 2014 | D | Indefinite similar: $500,000–$7,000,000 | $2,969,958 | 30 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Clovis Oncology, Inc. | Director | Nov 27, 2013 | D | Indefinite similar: $1,694,259–$16,000,000 | $191,962,756 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Applied Proteomics, Inc. | Director | Sep 25, 2013 | D | $27,863,715 similar: $2,000,000–$19,999,994 | $27,863,715 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NeuroPace Inc | Director | Jul 9, 2013 | D | $50,000,006 | $18,051,777 | 20 | No minimum reported |
| EDGAR ↗ | IntegenX Inc | Director | Dec 28, 2012 | D/A | $50,002,806 | $48,840,108 | 16 | No minimum reported |
| EDGAR ↗ | Astute Medical, Inc. | Director | Dec 24, 2012 | D | $500,000 | $500,000 | 1 | No minimum reported |
| EDGAR ↗ | IntegenX Inc | Director | Aug 23, 2012 | D/A | $50,002,806 | $39,439,659 | 13 | No minimum reported |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | Aug 1, 2012 | D | $19,400,000 | $19,400,000 | 1 | No minimum reported |
| EDGAR ↗ | Astute Medical, Inc. | Director | Jun 14, 2012 | D | $40,450,000 | $40,449,738 | 34 | No minimum reported |
| EDGAR ↗ | Astute Medical, Inc. | Director | May 25, 2012 | D | Indefinite | $2,000,200 | 14 | No minimum reported |
| EDGAR ↗ | Applied Proteomics, Inc. | Director | Apr 27, 2012 | D | $22,499,993 | $22,499,993 | 17 | No minimum reported |
| EDGAR ↗ | IntegenX Inc | Director | Nov 10, 2011 | D | $24,999,998 | $24,999,998 | 13 | No minimum reported |
| EDGAR ↗ | NeuroPace Inc | Director | Aug 30, 2011 | D | $61,914,481 | $49,126,004 | 22 | No minimum reported |
| EDGAR ↗ | Ocunexus Therapeutics, Inc. | Director | May 13, 2011 | D | $35,000,000 | $19,200,000 | 4 | $100,000 |
| EDGAR ↗ | Astute Medical, Inc. | Director | Mar 9, 2011 | D | $13,026,268 | $6,513,134 | 22 | No minimum reported |
| EDGAR ↗ | IntegenX Inc | Director | Mar 2, 2011 | D | $20,623,758 | $20,623,758 | 14 | No minimum reported |
| EDGAR ↗ | CELL BIOSCIENCES INC | Director | Nov 1, 2010 | D | $21,201,335 | $20,001,335 | 14 | No minimum reported |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Sep 16, 2010 | D | $7,499,999 | $7,499,999 | 1 | No minimum reported |
| EDGAR ↗ | ZOGENIX INC | Director | Jul 14, 2010 | D | $15,000,000 | $15,000,000 | 13 | No minimum reported |
| EDGAR ↗ | Astute Medical, Inc. | Director | May 17, 2010 | D | $26,560,375 | $26,560,375 | 23 | No minimum reported |
| EDGAR ↗ | CELL BIOSCIENCES INC | Director | Dec 21, 2009 | D | $9,750,000 | $9,249,999 | 3 | No minimum reported |
| EDGAR ↗ | ZOGENIX INC | Director | Dec 15, 2009 | D/A | $70,962,156 | $70,962,156 | 14 | No minimum reported |
| EDGAR ↗ | CELL BIOSCIENCES INC | Director | Nov 12, 2009 | D | $17,642,029 | $15,018,337 | 10 | No minimum reported |
| EDGAR ↗ | Helixis Inc | Director | Oct 27, 2009 | D/A | $10,000,001 | $7,333,335 | 12 | No minimum reported |
| EDGAR ↗ | ZOGENIX INC | Director | Oct 5, 2009 | D | $60,457,956 | $35,957,968 | 13 | No minimum reported |
| EDGAR ↗ | ZOGENIX INC | Director | Jul 28, 2009 | D | Indefinite | $3,100,000 | 9 | No minimum reported |
| EDGAR ↗ | Helixis Inc | Director | Jul 9, 2009 | D | $10,000,001 | $5,383,335 | 11 | No minimum reported |
| EDGAR ↗ | ZOGENIX INC | Director | Jun 29, 2009 | D | Indefinite | $3,100,000 | 9 | No minimum reported |
| EDGAR ↗ | Domain Partners VIII, L.P. group: Domain | Executive Officer | Jun 18, 2009 | D | Indefinite | $371,070,000 | 32 | $5,000,000 |
| EDGAR ↗ | DP VIII Associates, L.P. group: Domain | Executive Officer | Jun 10, 2009 | D | Indefinite | $3,673,000 | 35 | $50,000 |
| EDGAR ↗ | ZOGENIX INC | Director | May 29, 2009 | D | Indefinite | $3,100,000 | 9 | No minimum reported |
| EDGAR ↗ | CELL BIOSCIENCES INC | Director | Apr 20, 2009 | D | $10,592,611 | $5,000,004 | 11 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (6 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as James Blair. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when James Blair appears on a new Form D, or when a court case or SEC action is matched to them. See plans →